title: Immunoglobulin IV (Intragram®P)
text: |
  Immunoglobulin IV (Intragram®P)
  |
  bet | 295/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Immunoglobulin IV (Intragram®P):
  Revision Date : 22-12-2020
  |
  Approved: TC, KOH
  |
  Alert
  |
  If the patient has ANY adverse reaction, stop infusion and call a medical officer IMMEDIATELY.
  This formulary is for Intragam 10.
  Intragam 10 is the domestically produced intravenous immunoglobulin (IVIg) and is the most likely product that you will receive from the Australian Blood Service.
  Intragam P (6%) is no longer produced as of June 2018.
  Flebogamma 5% and 10% should not be given to neonates due to undiagnosed hereditary fructose intolerance.
  Other preparations such as Privigen 10 are available for paediatric use, but beyond the scope of this formulary.
  |
  Indication
  |
  Neonatal alloimmune thrombocytopenia (NAIT)
  Haemolytic disease of the newborn (HDN) (isoimmunisation)
  Immune thrombocytopenic purpura
  Primary immunodeficiency diseases
  Secondary hypogammaglobulinaemia
  Neonatal haemochromatosis – gestational alloimmune liver disease (GALD)
  Neonatal myasthenia gravis
  Severe neonatal enterovirus infection including myocarditis or hepatitis
  Sepsis/infection – prevention and treatment – NOT RECOMMENDED.
  1, 3-5, and 7 are approved indications by the National Blood Authority of Australia, 6 is a proposed addition as of June 2018.
  See https://www.criteria.blood.gov.au/ for a comprehensive list.
  Indications not funded under the Criteria for the clinical use of intravenous immunoglobulin in Australia (Criteria), may be provided for locally under Jurisdictional Direct Orders (https://www.blood.gov.au/system/files/documents/jdo-factsheet.pdf).
  At Canberra Hospital, IVIG (Privigen) can be procured under JDO for isoimmune haemolytic jaundice. It is purchased by pharmacy and can be accessed by Neonatology Staff through pathology for release on request if meeting following criteria:
  |
  |
  | |